舌下特异性免疫治疗对变应性鼻炎患者临床疗效及呼出气一氧化氮水平的影响  

Effects of sublingual specific immunotherapy on clinical efficacy and exhaled nitric oxide levels in patients with allergic rhinitis

作　　者：陈丽鸿[1] 江洪[1] 龙宇[1] 蒋凤 刘成刚[2] CHEN Lihong;JIANG Hong;LONG Yu;JIANG Feng;LIU Chenggang(Department of Otolaryngology Head and Neck Surgery;Department of Ophthalmology,The Affiliated Yongchuan Hospital of Chongqing Medical University,Chongqing 402160,China)

机构地区：[1]重庆医科大学附属永川医院耳鼻咽喉头颈外科,重庆402160 [2]重庆医科大学附属永川医院眼科,重庆402160

出　　处：《现代医药卫生》2025年第3期612-615,共4页Journal of Modern Medicine & Health

基　　金：重庆市永川区自然科学基金计划项目(2023yc-jckx20029);重庆医科大学附属永川医院科研课题资助项目(YJLC202113)。

摘　　要：目的 探讨舌下特异性免疫治疗(SLIT)对变应性鼻炎(AR)患者临床疗效及呼出气一氧化氮(NO)水平的影响。方法 选取2021年12月至2023年12月该院收治的114例AR患者作为研究对象,将其分为观察组(76例)和对照组(38例)。对照组患者采用常规抗过敏药物治疗,观察组采用抗过敏药物联合SLIT治疗。比较2组患者治疗前后鼻炎症状总评分(TNSS)、药物评分(TMS)、视觉模拟量表评分(VAS)、鼻呼出气NO(nNO)、口呼出气NO(FeNO)、肺泡NO(CaNO)及鼻结膜炎生活质量调查问卷评分(RQLQ)。结果 观察组患者治疗1年后nNO、FeNO水平[(496.85±260.62)、(28.59±25.34)ppb]明显低于对照组[分别为(503.32±179.91)、(31.26±21.95)ppb],差异均有统计学意义(P<0.05)。观察组患者治疗1年后TNSS、TMS和VAS评分[(0.72±0.74)、(0.37±0.59)、(0.72±1.23)分]均明显低于对照组[(3.39±1.05)、(1.63±1.10)、(3.08±1.19)分],差异均有统计学意义(P<0.05)。观察组患者治疗1年后RQLQ评分在7个方面均明显低于对照组,差异均有统计学意义(P<0.05)。结论 SLIT联合药物治疗AR能够使患者获得更好的临床疗效及生活质量,并且能够改善患者nNO和FeNO水平。Objective To evaluate the effects of sublingual specific immunotherapy(SLIT)on the clinical efficacy and exhaled nitric oxide(NO)levels in patients with allergic rhinitis(AR).Methods A total of 114 AR patients admitted to the hospital from December 2021 to December 2023 were selected as the research objects,and they were divided into the observation group(76 cases)and the control group(38 cases).The patients in the control group were treated with conventional antiallergic drugs,and the patients in the observation group were treated with antiallergic drugs combined with SLIT.The total nasal symptom score(TNSS),total medication score(TMS),visual analogue scale(VAS)score,nasal exhaled nitric oxide(nNO),fractional exhaled nitric oxide(FeNO),concentration of alveolar nitric oxide(CaNO)and rhinoconjunctivitis quality of life questionnaire(RQLQ)were compared between the two groups before and after treatment.Results After one year of treatment,the levels of nNO and FeNO in the observation group[(496.85±260.62)ppb and(28.59±25.34)ppb]were significantly lower than those in the control group[(503.32±179.91)ppb and(31.26±21.95)ppb],and the differences were statistically significant(P<0.05).After one year of treatment,the scores of TNSS,TMS and VAS in the observation group[(0.72±0.74),(0.37±0.59),(0.72±1.23)points]were significantly lower than those in the control group[(3.39±1.05),(1.63±1.10),(3.08±1.19)points],and the differences were statistically significant(P<0.05).After one year of treatment,the RQLQ scores of patients in the observation group were significantly lower than those in the control group in seven aspects,and the differences were statistically significant(P<0.05).Conclusion SLIT combined drug therapy for AR resulted in better clinical outcomes and quality of life in patients,and improved nNO and FeNO levels.

关 键 词：舌下特异性免疫治疗 变应性鼻炎 临床疗效 一氧化氮 

分 类 号：R765.21[医药卫生—耳鼻咽喉科]